Stockscreener 앱 받기
62.73
2.09%
1.285
전일 마감가:
$61.45
열려 있는:
$61.74
하루 거래량:
846.49K
Relative Volume:
1.26
시가총액:
$4.29B
수익:
$136.86M
순이익/손실:
$-168.69M
주가수익비율:
-22.32
EPS:
-2.81
순현금흐름:
$-113.49M
1주 성능:
+1.19%
1개월 성능:
+6.00%
6개월 성능:
+12.84%
1년 성능:
+56.32%
1일 변동 폭
$61.00
$62.92
1주일 범위
$60.80
$64.00
52주 변동 폭
$39.46
$69.89
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
RYTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
62.73 | 4.29B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
GAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A. - Defense World
(RYTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $76.62 Average Target Price from Brokerages - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Rhumbline Advisers - Defense World
Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals at Goldman Sachs Conference: Strategic Focus on Rare Diseases - Investing.com Nigeria
Rhythm Pharma stock soars to all-time high of $69.7 - Investing.com Australia
Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - MSN
Millennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - Yahoo Finance
Jefferies maintains buy rating on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK
Citizens JMP maintains $84 target on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights - Investing.com
(RYTM) Proactive Strategies - news.stocktradersdaily.com
Stifel Nicolaus Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World
Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal - GuruFocus
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga
Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News
Stifel raises Rhythm Pharma stock target to $94, keeps Buy rating - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | - GuruFocus
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus
Ameriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
POMC Deficiency Obesity Market on Track for Major Expansion - openPR.com
(RYTM) Investment Analysis - news.stocktradersdaily.com
Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Gotham Asset Management LLC Sells 2,685 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $75.38 Consensus Price Target from Analysts - Defense World
Rhythm Pharmaceuticals Announces New Data Presentations on Patie - GuruFocus
(RYTM) On The My Stocks Page - news.stocktradersdaily.com
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | - GuruFocus
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program - GlobeNewswire
New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan
Raymond James Financial Inc. Buys New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
HC Wainwright Has Negative Estimate for RYTM Q2 Earnings - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing Earnings - Defense World
Needham & Company LLC Increases Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00 - Defense World
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance
Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances - Investing.com Canada
RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
Rhythm Pharmaceuticals (RYTM) Price Target Raised by Needham | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rhythm Pharmaceuticals Inc 주식 (RYTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| German Christopher Paul | Corporate Controller & CAO |
Jun 10 '25 |
Sale |
67.19 |
2,069 |
139,016 |
1,889 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jun 06 '25 |
Option Exercise |
6.80 |
7,031 |
47,811 |
26,240 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jun 06 '25 |
Sale |
68.05 |
7,031 |
478,435 |
19,209 |
1.11%
1.70%
자본화:
|
볼륨(24시간):